** chart after earnings **
REDWOOD CITY, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for severe lung disease, today reported financial results for the first quarter ended March 31, 2021.
Recent Highlights
- Reported worldwide revenue of $9.2 million in the first quarter of 2021, a 7% increase over the same period last year
- Achieved gross margin of 71.5% in the first quarter of 2021 as compared to 65.6% in the same period last year
- Increased number of U.S. Zephyr Valve treating centers from 148 to 160
- Expanded U.S. sales management team from 6 to 9 regional directors while increasing total number of U.S. sales territory managers from 45 to 51
- Experienced a recovery in U.S. procedures in March as hospital constraints from the winter COVID-19 surge began to subside
“We are pleased with our first quarter performance and the resilience of our U.S. business which is showing substantial improvement as we progress through 2021. Procedures began recovering meaningfully in March, and we continue to make strides in expanding our team and our base of treatment centers. In Europe, the pandemic continues to evolve regionally, and we look forward to normalization later in the year,” said Glen French, President & Chief Executive Officer. “I believe we are well-positioned for further commercial momentum as we drive toward becoming the global leader in minimally invasive treatments for severe lung disease."
No comments:
Post a Comment